Skip to content
HowShorted

Intellia Therapeutics, Inc. short interest in 2022

In 2022, Intellia Therapeutics, Inc.'s disclosed short interest ran from 5.85% of shares outstanding on 14 Jan 2022 to 8.43% on 30 Dec 2022, a change of +2.58 percentage points. The year's high was 9.85% on 30 Jun 2022 and its low 5.85% on 14 Jan 2022, averaging 8.24% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.78 days on 30 Nov 2022. Full history: Intellia Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Intellia Therapeutics, Inc. in 2022

2022 in figures

Start of year
5.85% (14 Jan 2022)
End of year
8.43% (30 Dec 2022)
Change
+2.58 pp
High
9.85% (30 Jun 2022)
Low
5.85% (14 Jan 2022)
Average
8.24%
Highest days to cover
9.78 (30 Nov 2022)
SEC filings marked
9

Every report in 2022

Intellia Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20225.85%4.19results (8-K)
31 Jan 20226.45%3.89
15 Feb 20226.64%5.16
28 Feb 20227.12%4.7010-K filed, results (8-K)
15 Mar 20227.22%3.21
31 Mar 20227.55%5.66
14 Apr 20227.64%6.33
29 Apr 20228.23%6.80
13 May 20229.16%4.6110-Q filed, results (8-K)
31 May 20228.74%7.29
15 Jun 20229.21%5.56
30 Jun 20229.85%4.17
15 Jul 20229.51%5.17
29 Jul 20228.89%6.95
15 Aug 20229.17%4.9310-Q filed, results (8-K)
31 Aug 20229.04%7.65
15 Sep 20228.79%5.97
30 Sep 20229.04%4.74
14 Oct 20228.66%6.93
31 Oct 20228.91%7.85
15 Nov 20228.46%7.3210-Q filed, results (8-K)
30 Nov 20227.65%9.78
15 Dec 20227.56%2.99
30 Dec 20228.43%5.58

See also: Intellia Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.